A novel class of small molecule inhibitors of Hsp90.
Unregulated cellular proliferation, caused by mutation or dysregulation of growth-promoting proteins, is an underlying cause of cancer. Many such growth-promoting proteins exhibit an increased dependence on the activity of the chaperone heat-shock protein 90 (Hsp90) for correct folding and maturation in the cell. One can therefore envision that inhibition of Hsp90 would be an effective and broadly applicable strategy for the development of anticancer agents. Hsp90 functions in multichaperone complexes driven by the binding and hydrolysis of ATP. Encouraging results have been obtained by inhibiting Hsp90 with 17-AAG, an active-site binding ATP analog. Here we present the results of a different approach to inhibiting Hsp90 by disrupting its interaction with a cochaperone named Hsp organizing protein (HOP). We have used an AlphaScreen technology based high-throughput in vitro screen to identify compounds that inhibit this interaction. In addition, we demonstrate that these compounds are active in vivo. Treatment of human breast cancer cell lines BT474 and SKBR3 with these compounds decreases the levels of the Hsp90-dependent client protein HER2, with associated cell death.
Yi
Fang
F
Department of Molecular Biophysics & Biochemistry, Yale University, 266 Whitney Avenue, New Haven, Connecticut 06520, USA.
Regan
Lynne
L
D016588:Anticarcinogenic Agents / Q000737:chemistry* / Q000494:pharmacology*; D016227:Benzoquinones / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic / Q000737:chemistry / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D016588:Anticarcinogenic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D018719:Erb-b2 Receptor Tyrosine Kinases; C112765:tanespimycin
J Biol Chem. 1998 Dec 25;273(52):35194-200
9857057
Clin Cancer Res. 2007 Mar 15;13(6):1769-74
17363531
Science. 1987 Jan 9;235(4785):177-82
3798106
FEBS Lett. 2007 Jul 31;581(19):3758-69
17559840
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8
8078881
Cancer Res. 2002 Jul 15;62(14):4132-41
12124352
Chem Pharm Bull (Tokyo). 1975 Sep;23(9):2001-9
171091
Clin Cancer Res. 2007 Mar 15;13(6):1775-82
17363532
ACS Chem Biol. 2008 Mar 20;3(3):161-6
18355005
J Biosci. 2007 Apr;32(3):517-30
17536171
Nat Protoc. 2006;1(2):550-3
17191086
Cell Cycle. 2003 Nov-Dec;2(6):579-84
14512773
Curr Med Chem. 2007;14(29):3122-38
18220746
J Mol Biol. 2008 Jun 13;379(4):732-44
18485364
J Biol Chem. 2005 Nov 18;280(46):38729-39
16172114
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15422-7
17032757
Ann Oncol. 2008 Feb;19(2):269-75
17998285
Nat Med. 2000 Apr;6(4):443-6
10742152
Ann Oncol. 2001;12 Suppl 1:S23-8
11521717
Carbohydr Res. 2007 Jul 2;342(9):1254-60
17412311
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
Cell. 2000 Apr 14;101(2):199-210
10786835
J Clin Oncol. 2005 Jun 20;23(18):4152-61
15961763
Trends Endocrinol Metab. 1998 Aug;9(6):244-52
18406276
Cancer Res. 2001 May 15;61(10):4003-9
11358818